

CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )
F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd S.K. Tower,Hari Niwas, LBS Marg THANE, 400602

MAHARASHTRA, INDIA Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: HARSHADA P SAGAR

PATIENT ID: HARSF311080181

ACCESSION NO: 0181VI000318 AGE: 41 Years SEX: Female

DRAWN: RECEIVED: 10/09/2022 09:58 REPORTED: 13/09/2022 15:16

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Results Biological Reference Interval Units **Final** 

# MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

COLOR METHOD: VISUAL INSPECTION  APPEARANCE METHOD: VISUAL INSPECTION  SPECIFIC GRAVITY 1.005  METHOD: IONIC CONCENTRATION METHOD  BLOOD COUNTS,EDTA WHOLE BLOOD  HEMOGLOBIN METHOD: SLS- HEMOGLOBIN DETECTION METHOD  RELD BLOOD CELL COUNT METHOD: HYDRODYNAMIC FOCUSING BY DC DETECTION  WHITE BLOOD CELL COUNT METHOD: FLUORESCENCE FLOW CYTOMETRY  PALE YELLOW  CLEAR  1.005  1.003 - 1.003  1.003 - 1.035  1.003 - 1.
APPEARANCE METHOD: VISUAL INSPECTION  SPECIFIC GRAVITY METHOD: IONIC CONCENTRATION METHOD  BLOOD COUNTS,EDTA WHOLE BLOOD  HEMOGLOBIN METHOD: SLS- HEMOGLOBIN DETECTION METHOD  RELD BLOOD CELL COUNT METHOD: HYDRODYNAMIC FOCUSING BY DC DETECTION  WHITE BLOOD CELL COUNT  8.22  4.0 - 10.0  thou/µL
METHOD: VISUAL INSPECTION  SPECIFIC GRAVITY  METHOD: IONIC CONCENTRATION METHOD  BLOOD COUNTS,EDTA WHOLE BLOOD  HEMOGLOBIN  METHOD: SLS- HEMOGLOBIN DETECTION METHOD  RED BLOOD CELL COUNT  METHOD: HYDRODYNAMIC FOCUSING BY DC DETECTION  WHITE BLOOD CELL COUNT  8.22  4.0 - 10.0  thou/µL
SPECIFIC GRAVITY METHOD: IONIC CONCENTRATION METHOD  BLOOD COUNTS,EDTA WHOLE BLOOD  HEMOGLOBIN METHOD: SLS- HEMOGLOBIN DETECTION METHOD  RELD BLOOD CELL COUNT METHOD: HYDRODYNAMIC FOCUSING BY DC DETECTION  WHITE BLOOD CELL COUNT  8.22  1.003 - 1.035  1.003 - 1.
METHOD: IONIC CONCENTRATION METHOD  BLOOD COUNTS,EDTA WHOLE BLOOD  HEMOGLOBIN /.5 Low 12.0 - 15.0 g/dL  METHOD: SLS- HEMOGLOBIN DETECTION METHOD  RELD BLOOD CELL COUNT 4.26 3.8 - 4.8 mil/µL  METHOD: HYDRODYNAMIC FOCUSING BY DC DETECTION  WHITE BLOOD CELL COUNT 8.22 4.0 - 10.0 thou/µL
BLOOD COUNTS,EDTA WHOLE BLOOD  HEMOGLOBIN METHOD: SLS- HEMOGLOBIN DETECTION METHOD  RELD BLOOD CELL COUNT METHOD: HYDRODYNAMIC FOCUSING BY DC DETECTION  WHITE BLOOD CELL COUNT 8.22 4.0 - 10.0 thou/µL
HEMOGLOBIN METHOD: SLS- HEMOGLOBIN DETECTION METHOD  RED BLOOD CELL COUNT METHOD: HYDRODYNAMIC FOCUSING BY DC DETECTION  WHITE BLOOD CELL COUNT 8.22 4.0 - 10.0 thou/µL
METHOD: SLS- HEMOGLOBIN DETECTION METHOD  RED BLOOD CELL COUNT 4.26 3.8 - 4.8 mil/µL  METHOD: HYDRODYNAMIC FOCUSING BY DC DETECTION  WHITE BLOOD CELL COUNT 8.22 4.0 - 10.0 thou/µL
RED BLOOD CELL COUNT       4.26       3.8 - 4.8       mil/µL         METHOD: HYDRODYNAMIC FOCUSING BY DC DETECTION       4.26       4.0 - 10.0       thou/µL         WHITE BLOOD CELL COUNT       8.22       4.0 - 10.0       thou/µL
METHOD: HYDRODYNAMIC FOCUSING BY DC DETECTION  WHITE BLOOD CELL COUNT 8.22 4.0 - 10.0 thou/µL
WHI ΙΕ BLOOD CELL COUNT 8.22 4.0 - 10.0 thou/μL
••
METHOD: FLUORESCENCE FLOW CYTOMETRY
PLAIELEI COUNT 485 High 150 - 410 thou/µL
METHOD: HYDRODYNAMIC FOCUSING BY DC DETECTION
RBC AND PLATELET INDICES
HEMATOCRIT <b>27.6 Low</b> 36.0 - 46.0 %
METHOD: CUMULATIVE PULSE HEIGHT DETECTION METHOD
MEAN CORPUSCULAR VOL 64.8 Low 83.0 - 101.0 fL
METHOD: CALCULATED FROM RBC & HCT
MEAN CORPUSCULAR HGB. 17.6 Low 27.0 - 32.0 pg
METHOD: CALCULATED FROM THE RBC & HGB
MEAN CORPUSCULAR HEMOGLOBIN 27.2 Low 31.5 - 34.5 g/dL
CONCENTRATION  METHOD: CALCULATED FROM THE HGB & HCT
MENTZER INDEX 15.2
RED CELL DISTRIBUTION WIDTH 19.3 High 11.6 - 14.0 %
METHOD: CALCULATED FROM RBC SIZE DISTRIBUTION CURVE
MEAN PLATELET VOLUME 10.0 6.8 - 10.9 fL
METHOD: CALCULATED FROM PLATELET COUNT & PLATELET HEMATOCRIT
CHEMICAL EXAMINATION, URINE
PH 6.0 4.7 - 7.5
METHOD: DOUBLE INDICATOR PRINCIPLE
PROTEIN NOT DETECTED NOT DETECTED



METHOD: TETRA BROMOPHENOL BLUE/SULFOSALICYLIC ACID

Page 1 Ot 13 Scan to View Report



CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )
F-703, F-703, LADO SARAI, MEHRAULI
SOUTH WEST DELHI

NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd

S.K. Tower,Hari Niwas, LBS Marg THANE, 400602 MAHARASHTRA, INDIA Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: HARSHADA P SAGAR

PATIENT ID: HARSF311080181

ACCESSION NO: 0181VI000318 AGE: 41 Years SEX: Female

DRAWN: RECEIVED: 10/09/2022 09:58 REPORTED: 13/09/2022 15:16

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results	Biological Reference Interv	al Units
GLUCOSE	NOT DETECTED	NOT DETECTED	
METHOD: GLUCOSE OXIDASE PEROXIDASE			
KETONES	NOT DETECTED	NOT DETECTED	
METHOD: NITROPRUSSIDE REACTION			
BLOOD	NOT DETECTED	NOT DETECTED	
METHOD: PEROXIDASE			
UROBILINOGEN	NORMAL	NORMAL	
METHOD: MODIFIED EHRLICH REACTION			
NITRITE	NOT DETECTED	NOT DETECTED	
METHOD: 1,2,3,4-TETRAHYDROBENZO(H)QUINOLIN-3-OL	NOT DETENTED	NOT DETENTED	
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED	
WBC DIFFERENTIAL COUNT - NLR			
SEGMENTED NEUTROPHILS	66	40 - 80	%
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING			
ABSOLUTE NEUTROPHIL COUNT	5.43	2.0 - 7.0	thou/µL
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING			
LYMPHOCYTES	30	20 - 40	%
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING	0.47	10.00	
ABSOLUTE LYMPHOCYTE COUNT	2.47	1.0 - 3.0	thou/µL
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING	2.4		
NEUTROPHIL LYMPHOCYTE RATIC (NLR)	2.1		0/
EOSINOPHILS	01	1 - 6	%
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING	0.00	0.00 0.50	He and find
ABSOLUTE EOSINOPHIL COUNT	0.08	0.02 - 0.50	thou/µL
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING	03	2 - 10	%
MONOCYTES  METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING	03	2 - 10	70
ABSOLUTE MONOCYTE COUNT	0.25	0.2 - 1.0	thou/µL
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING	0.23	0.2 - 1.0	шоаурс
DIFFERENTIAL COUNT PERFORMED ON:	EDTA SMEAR		
MICROSCOPIC EXAMINATION, URINE	ED LA OMENIA		
	2-3	0-5	/HPF
PUS CELL (WBC'S) METHOD: MICROSCOPIC EXAMINATION	Z-J	0-3	/LIPE
EPITHELIAL CELLS	0-1	0-5	/HPF
METHOD: MICROSCOPIC EXAMINATION	0 1	0.0	) I IEI
ERYTHROCYTES (RBC'S)	NOT DETECTED	NOT DETECTED	/HPF
METHOD: MICROSCOPIC EXAMINATION	.,0, 52,20,25		,
CASTS	NOT DETECTED		
	· - · · - <del>- · · ·</del>		







CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )
F-703, F-703, LADO SARAI, MEHRAULI
SOUTH WEST DELHI

NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd S.K. Tower,Hari Niwas, LBS Marg THANE, 400602 MAHARASHTRA, INDIA Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

PATIENT ID: HARSF311080181

Email: customercare.thane@srl.in

< 200

200 - 239 High cholesterol > / = 240

Borderline high cholesterol

PATIENT NAME: HARSHADA P SAGAR

ACCESSION NO: 0181VI000318 AGE: 41 Years SEX: Female

RECEIVED: 10/09/2022 09:58 DRAWN: REPORTED: 13/09/2022 15:16

REFERRING DOCTOR: SELF			CLIENT PATIENT ID :	
Test Report Status <u>Final</u>	Results		Biological Reference Interv	al Units
METHOD: MICROSCOPIC EXAMINATION	NOT DETECTED			
CRYSTALS	NOT DETECTED			
METHOD: MICROSCOPIC EXAMINATION	NOT DETECTED		NOT DETECTED	
BACTERIA	NOT DETECTED		NOT DETECTED	
METHOD: MICROSCOPIC EXAMINATION	NOT DETECTED		NOT DETECTED	
YEAST	NOT DETECTED		NOT DETECTED	
MORPHOLOGY				
RBC	MICROCYTOSIS,HYP	OCHRO	DMASIA & ANISOCYTOSIS SEEN.	
WBC	NORMAL MORPHOLO	DGY		
METHOD: MICROSCOPIC EXAMINATION				
PLATELETS	INCREASED			
REMARKS	ADVICE:-IRON STU	DIES		
ERYTHRO SEDIMENTATION RATE, BLOOD				
SEDIMENTATION RATE (ESR) METHOD: WESTERGREN METHOD	23	High	0 - 20	mm at 1 hr
GLYCOSYLATED HEMOGLOBIN, EDTA WHOLE BI	LOOD			
GLYCOSYLATED HEMOGLOBIN (HBA1C)	5.7		Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 ADA Target: 7.0 Action suggested: > 8.0	%
METHOD: HPLC				
MEAN PLASMA GLUCOSE	116.9	High	< 116.0	mg/dL
METHOD : CALCULATED PARAMETER				
GLUCOSE, FASTING, PLASMA				
GLUCOSE, FASTING, PLASMA	97		Normal 75 - 99 Pre-diabetics: 100 - 125 Diabetic: > or = 126	mg/dL
METHOD: ENZYMATIC REFERENCE METHOD WITH HEXOKINASE				
GLUCOSE, POST-PRANDIAL, PLASMA				
GLUCOSE, POST-PRANDIAL, PLASMA	93		70 - 139	mg/dL
METHOD: ENZYMATIC REFERENCE METHOD WITH HEXOKINASE				
CORONARY RISK PROFILE, SERUM				
CHOLESTEROL	150		Desirable cholesterol level	mg/dL

METHOD: ENZYMATIC COLORIMETRIC ASSAY



Page 3 Ot 13 Scan to View Report



CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )
F-703, F-703, LADO SARAI, MEHRAULI
SOUTH WEST DELHI

NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd

S.K. Tower,Hari Niwas, LBS Marg THANE, 400602 MAHARASHTRA, INDIA Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

PATIENT ID: HARSF311080181

Email: customercare.thane@srl.in

PATIENT NAME: HARSHADA P SAGAR


ACCESSION NO: 0181VI000318 AGE: 41 Years

DRAWN: RECEIVED: 10/09/2022 09:58 REPORTED: 13/09/2022 15:16

SEX: Female

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results		Biological Reference Interv	al Units
TRIGLYCERIDES	85		Normal: < 150 Borderline high: 150 - 199 High: 200 - 499 Very High: >/= 500	mg/dL
METHOD : ENZYMATIC COLORIMETRIC ASSAY	20.6	Laur	Law LIDL Chalasharal (40)	
HDL CHOLESTEROL	28.6	LOW	Low HDL Cholesterol <40	mg/dL
			High HDL Cholesterol >/= 60	
METHOD: ENZYMATIC, COLORIMETRIC				
CHOLESTEROL LDL	104	High	Adult levels: Optimal < 100 Near optimal/above optimal: 1 129 Borderline high: 130-159 High: 160-189 Very high: = 190	mg/dL 00-
METHOD: ENZYMATIC COLORIMETRIC ASSAY				
NON HDL CHOLESTEROL	121		Desirable: < 130 Above Desirable: 130 -159 Borderline High: 160 - 189 High: 190 - 219 Very high: > / = 220	mg/dL
CHOL/HDL RATIO	5.2	High	Low Risk: 3.3 - 4.4 Average Risk: 4.5 - 7.0 Moderate Risk: 7.1 - 11.0 High Risk: > 11.0	
LDL/HDL RATIO	3.6	High	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk	
VERY LOW DENSITY LIPOPROTEIN	17.0		< OR = 30.0	mg/dL
LIVER FUNCTION PROFILE, SERUM				
BILIRUBIN, TOTAL METHOD: COLORIMETRIC DIAZO	0.52		Upto 1.2	mg/dL
BILIRUBIN, DIRECT	0.25		< 0.30	mg/dL
BILIRUBIN, INDIRECT	0.27		0.1 - 1.0	mg/dL
TOTAL PROTEIN	7.5		6.0 - 8.0	g/dL
METHOD: COLORIMETRIC				
ALBUMIN	4.6		3.97 - 4.94	g/dL
METHOD: COLORIMETRIC				
GLOBULIN	2.9		2.0 - 3.5	g/dL
ALBUMIN/GLOBULIN RATIO	1.6		1.0 - 2.1	RATIO
ASPARTATE AMINOTRANSFERASE (AST/SGOT)  METHOD: UV ABSORBANCE	20		< OR = 35	U/L









CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )
F-703, F-703, LADO SARAI, MEHRAULI
SOUTH WEST DELHI

NEW DELHI 110030 DELHI INDIA 8800465156

S.K. Tower,Hari Niwas, LBS Marg THANE, 400602 MAHARASHTRA, INDIA Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

SRL Ltd

PATIENT ID: HARSF311080181

Email: customercare.thane@srl.in

PATIENT NAME: HARSHADA P SAGAR

ACCESSION NO: 0181VI000318 AGE: 41 Years SEX: Female

DRAWN: RECEIVED: 10/09/2022 09:58 REPORTED: 13/09/2022 15:16

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results		Biological Reference I	nterval Units
ALANINE AMINOTRANSFERASE (ALT/SGPT)	11		< OR = 35	U/L
METHOD : UV ABSORBANCE ALKALINE PHOSPHATASE	43		35 - 104	U/L
METHOD: COLORIMETRIC	.0		00 10 1	٥, ١
GAMMA GLUTAMYL TRANSFERASE (GGT)	7		0 - 40	U/L
METHOD : ENZYMATIC, COLORIMETRIC				
LACTATE DEHYDROGENASE	186		125 - 220	U/L
METHOD: UV ABSORBANCE				
SERUM BLOOD UREA NITROGEN				
BLOOD UREA NITROGEN	5	Low	6 - 20	mg/dL
METHOD : ENZYMATIC ASSAY				
CREATININE, SERUM	0.65		0.5.00	C II
CREATININE	0.65		0.5 - 0.9	mg/dL
METHOD : COLORIMETRIC BUN/CREAT RATIO				
BUN/CREAT RATIO	7,69	Low	8.0 - 15.0	
URIC ACID, SERUM	7.09	LOW	0.0 - 15.0	
URIC ACID	3.9		2.4 - 5.7	mg/dL
METHOD: ENZYMATIC COLORIMETRIC ASSAY	3.9		2.4 - 3.7	mg/ac
TOTAL PROTEIN, SERUM				
TOTAL PROTEIN	7.5		6.0 - 8.0	g/dL
METHOD : COLORIMETRIC				9, 42
ALBUMIN, SERUM				
ALBUMIN	4.6		3.97 - 4.94	g/dL
METHOD: COLORIMETRIC				
GLOBULIN				
GLOBULIN	2.9		2.0 - 3.5	g/dL
ELECTROLYTES (NA/K/CL), SERUM				
SODIUM	134	Low	136 - 145	mmol/L
POTASSIUM	5.0		3.5 - 5.1	mmol/L
CHLORIDE	101		98 - 107	mmol/L
THYROID PANEL, SERUM				
T3	124.0		80 - 200	ng/dL
METHOD: ELECTROCHEMILUMINESCENCE				
T4	8.88		5.1 - 14.1	μg/dL
METHOD: ELECTROCHEMILUMINESCENCE				
TSH 3RD GENERATION	3.660		0.27 - 4.2	μIU/mL







ACROFEMI HEALTHCARE LTD ( MEDIWHEEL ) F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI DELHI INDIA 8800465156

NEW DELHI 110030

MAHARASHTRA, INDIA Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

S.K. Tower, Hari Niwas, LBS Marg

SRL Ltd

THANE, 400602

PATIENT NAME: HARSHADA P SAGAR

PATIENT ID: HARSF311080181

ACCESSION NO: 0181VI000318 AGE: 41 Years SEX: Female

DRAWN: RECEIVED: 10/09/2022 09:58 REPORTED: 13/09/2022 15:16

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Results Biological Reference Interval Test Report Status Units <u>Final</u>

METHOD: ELECTROCHEMILUMINESCENCE

PAPANICOLAOU SMEAR

TEST METHOD CONVENTIONAL GYNEC CYTOLOGY

SPECIMEN TYPE P 1018/22

TWO UNSTAINED CERVICAL SMEARS RECEIVED

2014 BETHESDA SYSTEM FOR REPORTING CERVICAL CYTOLOGY REPORTING SYSTEM

SPECIMEN ADEQUACY SATISFACTORY

THE SMEARS SHOW MAINLY SUPERFICIAL SQUAMOUS CELLS, FEW MICROSCOPY

INTERMEDIATE SQUAMOUS CELLS, FEW PARABASAL CELLS, OCCASIONAL SQUAMOUS METAPLASTIC CELLS, AND MANY CLUSTERS OF ENDOCERVICAL CELLS IN THE BACKGROUND OF MODERATE

POLYMORPHS & RBC""S. FEW PARABASAL CELLS SEEN.

INTERPRETATION / RESULT NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY

Comments

PLEASE NOTE PAPANICOLAU SMEAR STUDY IS A SCREENING PROCEDURE FOR CERVICAL CANCER WITH INHERENT FALSE NEGATIVE RESULTS HENCE SHOULD BE INTERPRETED WITH CAUTION. NO CYTOLOGICAL EVIDENCE OF HPV INFECTION IN THE SMEARS STUDIED. SMEARS WILL BE PRESERVE FOR 5 YEARS ONLY.

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP TYPE AB

METHOD: GEL COLUMN AGGLUTINATION METHOD.

RH LYPE **POSITIVE** 

METHOD: GEL COLUMN AGGLUTINATION METHOD.

XRAY-CHEST

**IMPRESSION** NO ABNORMALITY DETECTED

TMT OR ECHO

TMT OR ECHO 2D ECHO :-

Structurally normal valves.

No RWMA.

Good Left Ventricular systolic function. LVEF 60%

Normal LV Diastolic function. No e/o pulmonary hypertension

**ECG** 

ECG WITHIN NORMAL LIMITS

MAMOGRAPHY (BOTH BREASTS)

MAMOGRAPHY 30TH BREASTS ECTOPIC BREAST TISSUE BILATERALLY.

DENSE BREASTS.

MEDICAL HISTORY



Page 6 Ot 13 Scan to View Report



ACROFEMI HEALTHCARE LTD ( MEDIWHEEL ) F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI 8800465156

NEW DELHI 110030 DELHI INDIA

SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: HARSHADA P SAGAR PATIENT ID: HARSF311080181

ACCESSION NO: 0181VI000318 AGE: 41 Years SEX: Female

DRAWN: RECEIVED: 10/09/2022 09:58 REPORTED: 13/09/2022 15:16

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Results Biological Reference Interval Units <u>Final</u>

RELEVANT PRESENT HISTORY HYPOTHYROID SINCE 1 YEAR.

RELEVANT PAST HISTORY PAST H/O JAUNDICE.

RELEVANT PERSONAL HISTORY MARRIED / 3 CHILD / MIXED DIET / NO ALLERGIES / NO SMOKING / NO

14 YEARS BACK.

ALCOHOL

MENSTRUAL HISTORY (FOR FEMALES) REG.28-32/10-12. LMP (FOR FEMALES) 20/8/2022. OBSTETRIC HISTORY (FOR FEMALES) 3FTNDA2L3.

RELEVANT FAMILY HISTORY HIGH BLOOD PRESSURE: FATHER, GRANDMOTHER.

HEART DISEASE: FATHER. HISTORY OF MEDICATIONS THYRONORM 50mg.: 1-0-0. ayurvedic medications.

ANTHROPOMETRIC DATA & BMI

LCB (FOR FEMALES)

HEIGHT IN METERS 1.48 mts WEIGHT IN KGS. 65 Kas

BMI BMI & Weight Status as follows: kg/sqmts 30

Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese

GENERAL EXAMINATION

MENTAL / EMOTIONAL STATE NORMAL PHYSICAL ATTITUDE NORMAL GENERAL APPEARANCE / NUTRITIONAL STATUS OBESE BUILT / SKELETAL FRAMEWORK **AVERAGE** FACIAL APPEARANCE NORMAL NORMAL SKIN UPPER LIMB NORMAL LOWER LIMB NORMAL NECK NORMAL

NECK LYMPHATICS / SALIVARY GLANDS NOT ENLARGED OR TENDER

THYROID GLAND NOT ENLARGED CAROTID PULSATION NORMAL **TEMPERATURE** NORMAL

PULSE 78/MIN.REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO CAROTID

**BRUIT** 

RESPIRATORY RATE NORMAL

CARDIOVASCULAR SYSTEM







CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )
F-703, F-703, LADO SARAI, MEHRAULI
SOUTH WEST DELHI

NEW DELHI 110030 DELHI INDIA

8800465156

SRL Ltd

S.K. Tower,Hari Niwas, LBS Marg THANE, 400602 MAHARASHTRA, INDIA Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: HARSHADA P SAGAR PATIENT ID: HARSF311080181

ACCESSION NO: 0181VI000318 AGE: 41 Years SEX: Female

DRAWN: RECEIVED: 10/09/2022 09:58 REPORTED: 13/09/2022 15:16

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
PD	4 20 100 MM L 10	
BP	130/80 MM HG (SUPINE)	mm/Hg
PERICARDIUM	NORMAL	
APEX BEAT	NORMAL	
HEART SOUNDS	NORMAL	
MURMURS	ABSENT	
RESPIRATORY SYSTEM		
SIZE AND SHAPE OF CHEST	NORMAL	
MOVEMENTS OF CHEST	SYMMETRICAL	
BREATH SOUNDS INTENSITY	NORMAL	
BREATH SOUNDS QUALITY	VESICULAR (NORMAL)	
ADDED SOUNDS	ABSENT	
PER ABDOMEN		
APPEARANCE	NORMAL	
VENOUS PROMINENCE	ABSENT	
LIVER	NOT PALPABLE	
SPLEEN	NOT PALPABLE	
HERNIA	ABSENT	
CENTRAL NERVOUS SYSTEM		
HIGHER FUNCTIONS	NORMAL	
CRANIAL NERVES	NORMAL	
CEREBELLAR FUNCTIONS	NORMAL	
SENSORY SYSTEM	NORMAL	
MOTOR SYSTEM	NORMAL	
REFLEXES	NORMAL	
MUSCULOSKELETAL SYSTEM		
SPINE	NORMAL	
JOINTS	NORMAL	
BASIC EYE EXAMINATION		
CONJUNCTIVA	NORMAL	
EYELIDS	NORMAL	
EYE MOVEMENTS	NORMAL	
CORNEA	NORMAL	
DISTANT VISION RIGHT EYE WITHOUT GLASSES	REDUCED VISUAL ACUITY	6/24
DISTANCE VICTORIA PET EVE WITHOUT OF ACCES	DEDUCED VICUAL ACUITY	6/04

REDUCED VISUAL ACUITY 6/24



DISTANT VISION LEFT EYE WITHOUT GLASSES

Page 8 Ot 13 Scan to View Report



ACROFEMI HEALTHCARE LTD ( MEDIWHEEL ) F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI **NEW DELHI 110030** DELHI INDIA 8800465156

SRL Ltd S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

PATIENT ID:

HARSF311080181

Email: customercare.thane@srl.in

PATIENT NAME: HARSHADA P SAGAR

ACCESSION NO: 0181VI000318 AGE: 41 Years SEX: Female

DRAWN: RECEIVED: 10/09/2022 09:58 REPORTED: 13/09/2022 15:16

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Biological Reference Interval Test Report Status Results Units <u>Final</u>

NEAR VISION RIGHT EYE WITHOUT GLASSES REDUCED VISUAL ACUITY N/36 NEAR VISION LEFT EYE WITHOUT GLASSES REDUCED VISUAL ACUITY N/36

COLOUR VISION NORMAL

SHMMARY

RELEVANT HISTORY NOT SIGNIFICANT RELEVANT GP EXAMINATION FINDINGS OBESE: BMI 30

REDUCED ACUITY FOR DISTANT AND NEAR VISION.

REMARKS / RECOMMENDATIONS 1) OPHTHALMOLOGY CONSULT FOR REDUCED VISUAL ACUITY.

FOLLOW UP WITH GYNAECOLOGIST FOR CERVICAL EROSION.

3) TO DO S.IRON STUDIES

4) PHYSICIANS CONSULT FOR MANAGEMENT OF ANAEMIA

5) LOW FAT, LOW CALORIE, LOW CARBOHYDRATE, HIGH FIBRE DIET

6) IRON RICH DIET ADVISED. ADD GREEN LEAFY VEGETABLES, DATES

BEETROOT TO THE DAILY DIET.

7) REGULAR EXERCISE.REGULAR WALK FOR 30-40 MIN DAILY. 8) REPEAT LIPID PROFILE, CBC AFTER 3 MONTHS OF DIET AND

**EXERCISE** 

9) ENT CONSULTATION FOR FUTHER EVALUATION OF HEARING LOSS.

## Interpretation(s)

BLOOD COUNTS, EDTA WHOLE BLOOD-

The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. WBC DIFFERENTIAL COUNT – NLR-

The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504. This ratio element is a calculated parameter and out of NABL scope.

MICROSCOPIC EXAMINATION, URINE-

Routine urine analysis assists in screening and diagnosis of various metabolic, urological, kidney and liver disorders

Protein: Elevated proteins can be an early sign of kidney disease. Urinary protein excretion can also be temporarily elevated by strenuous exercise, orthostatic proteinuria, dehydration, urinary tract infections and acute illness with fever

Glucose: Uncontrolled diabetes mellitus can lead to presence of glucose in urine. Other causes include pregnancy, hormonal disturbances, liver disease and certain

Ketones: Uncontrolled diabetes mellitus car lead to presence of ketones in urine. Ketones can also be seen in starvation, frequent vomiting, pregnancy and strenuous exercise.

Blood: Occult blood can occur in urine as intact erythrocytes or haemoglobin, which can occur in various urological, nephrological and bleeding disorders.

Leukocytes: An increase in leukocytes is an indication of inflammation in urinary tract or kidneys. Most common cause is bacterial urinary tract infection.

Nitrite: Many bacteria give positive results when their number is high. Nitrite concentration during infection increases with length of time the urine specimen is retained in

bladder prior to collection.

pH: The kidneys play an important role in maintaining acid base balance of the body. Conditions of the body producing acidosis/ alkalosis or ingestion of certain type of food can affect the pH of urine.

Specific gravity: Specific gravity gives an indication of how concentrated the urine is. Increased specific gravity is seen in conditions like dehydration, glycosuria and proteinuria while decreased specific gravity is seen in excessive fluid intake, renal failure and diabetes insipidus. Bilirubin: In certain liver diseases such as biliary obstruction or hepatitis, bilirubin gets excreted in urine. Urobilinogen: Positive results are seen in liver diseases like hepatitis anc cirrhosis and in cases of hemolytic anemia

ERYTHRO SEDIMENTATION RATE, BLOODErythrocyte sedimentation rate (ESR) is a non - specific phenomena and is clinically useful in the diagnosis and monitoring of disorders associated with an increased production of acute phase reactants. The ESR is increased in pregnancy from about the 3rd month and returns to normal by the 4th week post partum. ESR is influenced by age, sex, menstrual cycle and drugs (eg. corticosteroids, contraceptives). It is especially low (0-1mm) in polycythaemia, hypofibrinogenemia or congestive cardiac failure







ACROFEMI HEALTHCARE LTD ( MEDIWHEEL ) F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI **NEW DELHI 110030** DELHI INDIA 8800465156

S.K. Tower, Hari Niwas, LBS Marg THANE, 400602 MAHARASHTRA, INDIA

SRL Ltd

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

PATIENT ID:

HARSF311080181

Email: customercare.thane@srl.in

PATIENT NAME: HARSHADA P SAGAR

ACCESSION NO: 0181VI000318 AGE: 41 Years SEX: Female

DRAWN: RECEIVED: 10/09/2022 09:58 REPORTED: 13/09/2022 15:16

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Results Biological Reference Interval Units Test Report Status <u>Final</u>

and when there are abnormalities of the redicells such as polkilocytosis, spherocytosis or sickle cells.

### Reference:

1. Nathan and Oskı's Haematology of Infancy and Childhood, 5th edition
2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin
3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th Edition" GLYCOSYLATED HEMOGLOBIN, EDTA WHOLE BLOOD-

Glycosylatec hemoglobin (GHb) has been firmly established as an index of long-term blood glucose concentrations and as a measure of the risk for the development of complications in patients with diabetes mellitus. Formation of GHb is essentially irreversible, and the concentration in the blood depends on both the life span of the rec blood cell (average 120 days) and the blood glucose concentration. Because the rate of formation of GHb is directly proportional to the concentration of glucose in the blood,

the GHb concentration represents the integrated values for glucose over the preceding 6-8 weeks.

Any condition that alters the life span of the red blood cells has the potential to alter the GHb level. Samples from patients with hemolytic anemias will exhibit decreased glycated hemoglobin values due to the shortened life span of the red cells. This effect will depend upon the severity of the anemia. Samples from patients with polycythemia or post-spienectomy may exhibit increased glycated hemoglobin values due to a somewhat longer life span of the red cells.

Glycosylated hemoglobins results from patients with HbSS, HbCC, and HbSC and HbD must be interpreted with caution, given the pathological processes, including anemia,

increased rec cell turnover, transfusion requirements, that adversely impact HbA1c as a marker of long-term glycemic control. Ir these conditions, alternative forms of testing such as glycated serum protein (fructosamine) should be considered.

Targets should be individualized; More or less stringent glycemic goals may be appropriate for individual patients. Goals should be individualized based on duration of diabetes, age/life expectancy, comorbid conditions, known CVD or advanced microvascular complications, hypoglycemia unawareness, and individual patient considerations."

## References

- 1. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, edited by Carl A Burtis, Edward R.Ashwood, David E Bruns, 4th Edition, Elsevier publication, 2006, 879-884.
- 2. Forsham PH. Diabetes Mellitus: A rational plan for management. Postgrad Med 1982, 71,139-154.
- 3. Mayer TK, Freedman ZR: Protein glycosylation in Diabetes Mellitus: A review of laboratory measurements and their clinical utility. Clin Chim Acta 1983, 127, 147-184. GLUCOSE, FASTING, PLASMA-

ADA 2021 guidelines for adults, after 8 hrs fasting is as follows:

Pre-diabetics: 100 - 125 mg/dL
Diabetic: > or = 126 mg/dL
GLUCOSE, POST-FRANDIAL, PLASMA-ADA Guidelines for 2hr post prandial glucose levels is only after ingestion of 75grams of glucose in 300 ml water, over a period of 5 minutes.

LIVER FUNCTION PROFILE, SERUM-LIVER FUNCTION PROFILE

Bilirubin is a yellowish pigment found in bile and is a breakdowr product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral intection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget's disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seer in Hypophosphatasia, Malnutrition, Protein deficiency, Wilson's disease. GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dystunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pandreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or c, Multiple myeloma, Waldenstrom's disease. Lower-than-normal levels may be due to: Agamm aglobulin emia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Mahnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc SERUM BLOOD UREA NITROGEN-

Causes of Increasec levels

Pre renal

High protein diet, Increasec protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal

Renal Failure

Post Renal

Malignancy, Nephrolithiasis, Prostatism







ACROFEMI HEALTHCARE LTD ( MEDIWHEEL ) F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI **NEW DELHI 110030** DELHI INDIA

8800465156

SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: HARSHADA P SAGAR PATIENT ID: HARSF311080181

ACCESSION NO: 0181VI000318 AGE: 41 Years SEX: Female

DRAWN: RECEIVED: 10/09/2022 09:58 REPORTED: 13/09/2022 15:16

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Results Biological Reference Interval **Test Report Status** Units <u>Final</u>

Causes of decreased levels

- Liver disease
- CREATININE, SERUM-

Higher than normal level may be due to:

Blockage in the urinary tract

- Kidney problems, such as kidney damage or failure, intection, or reduced blood flow
- Loss of body fluid (dehydration)
- Muscle problems, such as breakdown of muscle fibers
   Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:

- Myasthenia Gravis
- Muscular dystrophy URIC ACID, SERUM-

Causes of Increasec levels

Dietary

- High Protein Intake.
- Prolonged Fasting,
  Rapid weight loss.

Gout

Lesch nyhan syndrome.

Type 2 ĎM.

Metabolic syndrome

Causes of decreased levels

- Low Zinc Intake
- · Multiple Sclerosis

Nutritional tips to manage increased Uric acid levels

- Drink plenty of fluids
- Lmit animal proteins
- High Fibre foods
- Vit C Intake
- Antioxidant rich foods TOTAL PROTEIN, SERUM-

Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-

Human serum albumir is the most abundant protein in human blooc plasma. It is produced in the liver. Albumin constitutes about half of the blooc serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, mainutrition and wasting etc. ELECTROLYTES (NA/K/CL), SERUM-

Sodium levels are Increased in dehydration, cushing's syndrome, aldosteronism & decreased in Addison's disease, hypopituitarism, liver disease. Hypokalemia (low K) is common in vomiting, diarrhea, alcoholism, folic acid deficiency and primary aldosteronism. Hyperkalemia may be seen in end-stage renal failure, hemolysis, trauma, Addison's disease, metabolic acidosis, acute starvation, dehydration, and with rapid K infusion. Chloride is increased in dehydration, renal tubular acidosis (hyperchloremia metabolic acidosis), acute renal failure, metabolic acidosis associated with prolonged diarrhea and loss of sodium bicarbonate, diabetes insipidus, adrenocortical hyperfuction, salicylate intoxication and with excessive infusion of isotonic saline or extremely high dietary intake of salt. Chloride is decreased in overhydration, chronic

hyperfuction, salicylate intoxication and with excessive infusion of isotonic saline or extremely high dietary intake of salt. Chloride is decreased in overhydration, chronic respiratory acidosis, salt-losing nephritis, metabolic alkalosis, congestive heart failure, Addisoniar crisis, certain types of metabolic acidosis, persistent gastric secretion and prolonged vomiting,
THYROID PANEL, SERUMTriiodothyronine T3, is a thyroid hormone. It affects almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate. Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (T5H), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of T5H.

Thyroxine T4, Thyroxine's principal function is to stimulate the metabolism of all cells and tissues in the body. Excessive secretion of thyroxine in the body is

hyperthyroidism, and deficient secretion is called hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hypothyroidism, TSH levels are low.

Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3 Levels in TOTAL T4 TSH3G TOTAL T3

(µg/đL) Pregnancy (µIU/mL) (ng/dL) First Trimester 81 - 190 6.6 - 12.40.1 - 2.5



Page 11 Ot 13 Scan to View Report



ACROFEMI HEALTHCARE LTD ( MEDIWHEEL ) F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602

MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: HARSHADA P SAGAR

PATIENT ID: HARSF311080181

ACCESSION NO: 0181VI000318 AGE: 41 Years SEX: Female

DRAWN: RECEIVED: 10/09/2022 09:58 REPORTED: 13/09/2022 15:16

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Results Biological Reference Interval Units <u>Final</u>

2nd Trimester 6.6 - 15.5 0.2 - 3.0 100 - 260 6.6 - 15.50.3 - 3.03rc Trimester 100 - 260

Below mentioned are the guidelines for age related reference ranges for T3 and T4.

(µg/dL) 1-3 day: 8.2 - 19.9  $(ng/\underline{dL})$ New Born: 75 - 260 1 Week: 6.0 - 15.9

NOTE: TSH concentrations in apparently normal euthyroid subjects are known to be highly skewed, with a strong tailed distribution towards higher TSH values. This is well documented in the pediatric population including the infant age group.

Kindly note: Method specific reference ranges are appearing on the report under biological reference range.

1. Burts C.A., Ashwood E. R. Bruns D.E. Teitz textbook of Clinical Chemistry and Molecular Diagnostics, 4th Edition.

2. Gowenlock A.H. Varley's Practical Clinical Biochemistry, 6th Edition.

3. Behrman R.E. Kilegman R.M., Jenson H. B. Nelsor Text Book of Pediatrics, 17th Edition ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-

Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Flease note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.







CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )
F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd S.K. Tower,Hari Niwas, LBS Marg THANE, 400602

MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: HARSHADA P SAGAR

PATIENT ID: HARSF311080181

ACCESSION NO: 0181VI000318 AGE: 41 Years SEX: Female

RECEIVED: 10/09/2022 09:58 DRAWN: REPORTED: 13/09/2022 15:16

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Results Biological Reference Interval Units **Final** 

# MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

ULTRASOUND ABDOMEN ULTRASOUND ABDOMEN GRADE | FATTY LIVER. SEEDLING UTERINE FIBROID.

> \*\*End Of Report\*\* Please visit www.srlworld.com for related Test Information for this accession

Dr.Priyal Chinchkhede

Bhinchkhede

Consultant Pathologist

Dr. Ushma Wartikar Consultant Pathologist

Dr.(Mrs)Neelu K Bhojani

Lab Head



